Risk factors for intrahepatic recurrence of hepatocellular carcinoma in cirrhotic patients treated by percutaneous ethanol injection

✍ Scribed by Maurizio Pompili; Gian Ludovico Rapaccini; Francescantonio de Luca; Eugenio Caturelli; Antonio Astone; Domenico Angelo Siena; Maria Rosaria Villani; Anna Grattagliano; Augusto Cedrone; Giovanni Gasbarrini

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 111 KB
• Volume: 79
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/(sici)1097-0142(19970415)79:8<1501::aid-cncr9>3.0.co;2-d

✦ Synopsis

cirrhosis diagnosis. Furthermore, the posttreatment parameters of the AFP level 1 tolica del Sacro Cuore, Rome, Italy.

month after PEI and recurrence of HCC in the same liver segment were also 2 Divisione di Gastroenterologia, IRCCS Casa evaluated. Sollievo della Sofferenza, San Giovanni Rotondo

RESULTS.

The cumulative 4-year intrahepatic recurrence rate of HCC was 62%. The FG, Italy. log rank test indicated that, among pretreatment parameters, time from cirrhosis diagnosis ú6 years (P Å 0.05) and AFP level before PEI of ú25 ng/mL (P Å 0.00005) were significantly linked to tumor recurrence. Cox's proportional hazards model showed that only AFP level before PEI was independently associated with recurrence (P õ 0.002). With regard to posttreatment parameters, an AFP level 1 month after PEI of ú13 ng/mL was shown to be significantly related to tumor recurrence by the log rank test (P õ 0.0001). CONCLUSIONS. Cirrhotic patients with single HCC treated by PEI who have slightly increased serum levels of AFP before and/or after PEI treatment are at increased risk of intrahepatic tumor recurrence and should undergo a close follow-up program.